New guidelines from the American Heart Association and the American College of Cardiology are likely to boost demand for cholesterol-lowering statin drugs, many of which are already sold in generic form, analysts say. "It's going to be the largest generic makers who already have the facilities and the contracts in place to work with pharmacy benefit managers who are going to be benefiting the most from increased use of these generic drugs," said health economist Vivian Ho.

Related Summaries